Hofseth BioCare Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Jon Odegard
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -NOK 140m |
| Dec 31 2022 | n/a | n/a | -NOK 137m |
| Sep 30 2022 | n/a | n/a | -NOK 136m |
| Jun 30 2022 | n/a | n/a | -NOK 139m |
| Mar 31 2022 | n/a | n/a | -NOK 135m |
| Dec 31 2021 | n/a | n/a | -NOK 126m |
| Sep 30 2021 | n/a | n/a | -NOK 120m |
| Jun 30 2021 | n/a | n/a | -NOK 115m |
| Mar 31 2021 | n/a | n/a | -NOK 111m |
| Dec 31 2020 | NOK 2m | NOK 695k | -NOK 102m |
| Sep 30 2020 | n/a | n/a | -NOK 104m |
| Jun 30 2020 | n/a | n/a | -NOK 90m |
| Mar 31 2020 | n/a | n/a | -NOK 86m |
| Dec 31 2019 | NOK 2m | NOK 660k | -NOK 89m |
| Sep 30 2019 | n/a | n/a | -NOK 79m |
| Jun 30 2019 | n/a | n/a | -NOK 81m |
| Mar 31 2019 | n/a | n/a | -NOK 83m |
| Dec 31 2018 | NOK 2m | NOK 702k | -NOK 85m |
| Sep 30 2018 | n/a | n/a | -NOK 74m |
| Jun 30 2018 | n/a | n/a | -NOK 66m |
| Mar 31 2018 | n/a | n/a | -NOK 66m |
| Dec 31 2017 | NOK 2m | NOK 2m | -NOK 16m |
| Sep 30 2017 | n/a | n/a | -NOK 28m |
| Jun 30 2017 | n/a | n/a | -NOK 60m |
| Mar 31 2017 | n/a | n/a | -NOK 92m |
| Dec 31 2016 | NOK 2m | NOK 2m | -NOK 147m |
Compensation vs Market: Insufficient data to establish whether Jon's total compensation is reasonable compared to companies of similar size in the UK market.
Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.
CEO
Jon Odegard
less than a year
Tenure
NOK 1,701,000
Compensation
Mr. Jon Olav Odegard had been Chief Financial Officer of Hofseth BioCare ASA since August 29, 2016 until 2022 and serves as its Chief Executive Officer since August 1, 2022 and was its Chief Executive Offi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | NOK 1.70m | no data | |
| Chief Scientific Officer | 13.4yrs | NOK 21.73m | 1.32% NOK 14.3m | |
| Chief Commercial Officer | 2.3yrs | NOK 7.81m | no data | |
| Chief Quality Officer | 2.3yrs | NOK 822.00k | no data | |
| CFO & COO | less than a year | no data | no data | |
| Head of Medical R&D and Director | no data | no data | 0.19% NOK 2.1m | |
| EVP of Global Ingredients Division & CEO of HBC Switzerland GmbH | 1.8yrs | no data | no data |
2.0yrs
Average Tenure
Experienced Management: HBCO's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Head of Medical R&D and Director | 1.4yrs | no data | 0.19% NOK 2.1m | |
| Director | less than a year | no data | 17.59% NOK 191.1m | |
| Independent Director | 1.5yrs | no data | no data | |
| Independent Director | 8.4yrs | NOK 96.00k | 0.20% NOK 2.2m | |
| Independent Director | 8yrs | NOK 116.00k | 0.051% NOK 550.0k | |
| Independent Chair of the Board | 2.5yrs | no data | no data |
2.0yrs
Average Tenure
49yo
Average Age
Experienced Board: HBCO's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.